Has Thomas Newsom, MD received payments from drug or device companies?

Yes. Drug and device makers reported $186,173 in general payments to Thomas Newsom, MD across 118 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Thomas Newsom, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Thomas Newsom, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Thomas Newsom, MD

Ophthalmology · Tampa, FLNPI 1851386395

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $153,948 of the $186,173 with a category attached, or 82.7%. Rxsight Inc accounts for 86.6% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $130,436 and has fallen 92.7% since, to $9,469 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$186,173in general payments, 2019–2025

Across 118 payments — averaging $1577.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Rxsight Inc$161K
Rayner Intraocular Lenses Limited$8K
Bausch & Lomb Americas Inc.$8K
Alcon Research LLC$3K
Alcon$2K
Lensar, Inc.$2K
plus $1K from 8 others

$1,373,045in research payments, 2019–2025

Across 1,339 payments — averaging $1025.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Alcon Research LLC$858K
Rxsight Inc$448K
AbbVie$67K

What the payments were for

Consulting fees$153,94883%
Speaking & faculty fees$25,48414%
Travel & lodging$1,9601%
Food & beverage$4,6963%
Gifts$860%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Rxsight Inc	43	$161,284
Rayner Intraocular Lenses Limited	7	$8,295
Bausch & Lomb Americas Inc.	13	$8,067
Alcon Research LLC	1	$3,430
Alcon	26	$2,352
Lensar, Inc.	4	$1,654
Glaukos Corporation	3	$294
Johnson & Johnson Surgical Vision, Inc.	6	$174
Ivantis, Inc	2	$169
Sight Sciences, Inc.	2	$136
AbbVie(2 entities)	7	$118
Sun Pharmaceutical Industries Inc.	2	$108
Optovue, Inc.	1	$60
Omeros Corporation	1	$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$131,441
RXSIGHT CONTACT LENS$29,467
RXSIGHT INJECTOR CARTRIDGE$29,467
RXSIGHT INJECTOR HANDPIECE$29,467
RXSIGHT LIGHT DELIVERY DEVICE (LDD)$29,467
LIGHT ADJUSTABLE LENS (LAL)$17,496
RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$11,971
OMIDRIA$8,203
AcrySof IQ PanOptix$3,807
AcrySof IQ VIVITY IOL$3,798
LENSAR LASER SYSTEM$1,571
AcrySof$1,176
ENVISTA ENVY IOL$213
Photrexa Viscous and Photrexa$210
iDoseTR$210
KXL System$210
Hydrus Microstent$152
AcrySof IQ VIVITY$124
Tecnis IOL$124
OMNI(R) SURGICAL SYSTEM (US)$123

How this compares

$186,173 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida →

Medicare billing

Part B allowed, 2024

$820,532

Medicare patients

1,216

Services billed

4,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ProlensaBromfenac Sodium	144	$50,834
Prednisolone Acetate	721	$26,263
IlevroNepafenac	68	$24,781
Bromfenac Sodium	79	$14,208
Difluprednate	136	$13,232
Ketorolac Tromethamine	465	$10,449
MoxifloxacinMoxifloxacin Hcl	481	$10,235
Ofloxacin	413	$4,543
Latanoprost	205	$2,215
Brimonidine Tartrate	45	$1,273
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	72	$875
Diclofenac Sodium	55	$614
Timolol Maleate	53	$386
Dorzolamide Hcl	13	$207
ErythromycinErythromycin Base	16	$143

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Tampa

Courtney BoveeTampa$796K
Ivan SunerTampa$378K
Pedram HamrahTampa$187K
Don PerezTampa$178K
Brian SzaboTampa$86K
Cathleen McCabeBradenton$2M
Daniel KiernanSarasota$1.7M
David EichenbaumSt Petersburg$1.7M
Mark MilnerPalm Beach Gardens$1.2M
Neel DesaiLargo$1M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →